CD4 descriptions at various clinical HIV/AIDS stages with tuberculosis and non-tuberculosis opportunistic infections at dr. Zainoel Abidin hospital in Banda Aceh, Indonesia

1st International Conference on Tropical Medicine and Infectious Diseases (ICTROMI) Faculty of Medicine Universitas Sumatera Utara

Shaleh, A.S.^1 ; Fahrial^2 ; Siregar, M.L.^3 ; Jamil, K.F.^3

Department of Internal Medicine, Syiah Kuala University Medical School, Banda Aceh, Indonesia^1

Medical Faculty of Syiah Kuala University, Banda Aceh, Indonesia^2

Department of Internal Medicine, Division of Tropical and Infectious Diseases, Syiah Kuala University Medical School, Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia^3

关键词: Banda Aceh , Indonesia;    Cross-sectional design;    Descriptive studies;    Human immune systems;    Human immunodeficiency virus;    Medical record;    Opportunistic infections;    Secondary datum;   

Others  :  https://iopscience.iop.org/article/10.1088/1755-1315/125/1/012032/pdf
DOI  :  10.1088/1755-1315/125/1/012032

来源: IOP

【 摘 要 】

Human Immunodeficiency Virus (HIV) / Acquired Immune Deficiency Syndrome (AIDS) is a retrovirus that infects the human immune system. Damaged immunity in HIV/AIDS patients is marked by a decline in CD4 cells. Opportunistic infections appear differently, depending on the levels of immunosuppressive degrees, and the frequency of opportunistic infections in the environment. This study aims to describe the CD4 at various clinical stages of HIV/AIDS with tuberculosis and non-tuberculosis opportunistic infections (OI). Descriptive study with a cross-sectional design. This study is secondary data obtained from the medical records of patients with HIV/AIDS in the period of January 2011 - December 2015 at dr. Zainoel Abidin Hospital in Banda Aceh. The samples that met the inclusion criteria were 135 people with 63 cases were tuberculosis OI, 33 cases were non-tuberculosis and 39 cases were without OI. The study showed CD4 3was the highest level at all clinical stages (I-IV), with the prevalence of 85.7% for tuberculosis OI and 93.9% for non-tuberculosis OI.